Patterns and Outcomes of Subsequent Therapy After Immune Checkpoint Inhibitor Discontinuation in HCC

Muzaffar, MahvishBulumulle, AnushiSharma, Rohini2022-12-052022-12-0520222471-254Xhttp://hdl.handle.net/10342/11818en-USimmune checkpoint inhibitors (ICIs)hepatocellular cancer (HCC)tyrosine kinase inhibitors (TKIs)Patterns and Outcomes of Subsequent Therapy After Immune Checkpoint Inhibitor Discontinuation in HCCArticle10.1002/hep4.1927